+

Help Us Enhance Your NephU Experience

Help Us Enhance Your NephU Experience

User experience form

Email Address*(Required)

What is Your Specialty?*(Required)

Select all that apply (Select at least one)*

What are your goals for visiting NephU?(Required)

Learn about IgAN MOD and disease progression

Join the NephU community

Access additional IgAN resources

Select all that apply (Select at least one)*

How would you like to hear from us?(Required)

Biweekly Email Newsletters

Schedule a Meeting with a Medical Science Liaison

Learn About Upcoming Live/Virtual Events

Agree(Required)

By providing your name, email address, and other information, you are giving Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and companies working with OPDC permission to send you information from NephU. OPDC will not sell or transfer your name, address, or email address. You agree that should you use any material provided through NephU, you will attribute the source of that information to “NephU sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.” For additional information, please read our Privacy Policy. By submitting your information, you agree to the terms provided above, and the terms provided in our Terms of Use and our Privacy Policy.

*Required Field

Dana Rizk, MD

Professor of Medicine, Division of Nephrology Director of Clinical Trials, Division of Nephrology Medical Director, Clinical Trials Administrative Office

Dr Dana Rizk is Tenured Professor of Medicine in the Division of Nephrology at the University of Alabama at Birmingham (UAB). She also serves as Director of Clinical Trials Research in the Division of Nephrology and as Medical Director for the Clinical Trials Administrative Office (part of the CCTS) at UAB.

She has a passion for education and has served as a member of the Clinical Competency Committees for the Internal Medicine as well as the Nephrology Programs. She is the recipient of several teaching awards.

Her clinical and research interests revolve around glomerular diseases and, in particular IgA Nephropathy (IgAN). She has served as the site principal investigator on many clinical trials and is part of several multi-disciplinary translational research projects focused on the role of biomarkers in the diagnosis and prognosis of IgAN. Her research efforts have resulted in more than 60 peer-reviewed publications in prestigious medical journals including the New England Journal of Medicine.

Contact Dana Rizk

Areas of Expertise

Glomerular diseases, in particular IgA Nephropathy (IgAN)

Prior Experience

Served as a member of the Clinical Competency Committees for the Internal Medicine as well as the Nephrology Programs.

Schools Attended

American University of Beirut

Fellowships, Internships, & Residencies

NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.

May 2020 MRC2.CORP.X.04767

August 2024 US.CORP.X.24.00265

©2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved.